Boston College and Vanderbilt University
Alane was born and raised in a small town in central Maine. She earned her undergraduate degree in economics from Colby College and competed on their NCAA Division I alpine ski team. After Colby, Alane worked as an economic consultant on the financial analysis of Superfund site cleanups and for the Department of Energy on the long-term storage and disposal of spent nuclear fuel. Alane then decided to pursue a career in health care and earned graduate degrees from Boston College and Vanderbilt University. The focus of her doctoral research was on rural-urban disparities in the prevalence of chronic disease and her findings were published in Public Health.
Alane’s clinical work focuses on addiction medicine and the management of opioid use disorders using buprenorphine. She developed an integrated medical and behavioral health treatment program that has served hundreds of opioid dependent pregnant women. Alane received grant funding to write a treatment manual based on this integrated care model. She coordinates an elective in addiction medicine that many residents pursue during their third year. Alane has published her ground breaking research on infant outcomes following exposure to buprenorphine during pregnancy in many journals including the Journal of Maternal-Fetal and Neonatal Medicine, the Journal of Perinatal Medicine, European Addiction Research, and the American Journal of Obstetrics and Gynecology. She has academic appointments at Dartmouth Medical School and Vanderbilt University and is a peer reviewer for a variety of journals. Alane also serves on a public policy work group for the US Substance Abuse and Mental Health Services Administration that is working toward expanded access to treatment with buprenorphine. She is MDFMR’s representative to MaineGeneral’s Institutional Review Board which oversees all of the biomedical and behavioral research involving humans at MaineGeneral Medical Center.
Alane’s recent publications include:
O’Connor AB, O’Brien L, Alto WA. Maternal buprenorphine dose at delivery and its relationship to neonatal outcomes. Eur Addict Res 2016;22:127–130.
O’Connor AB, O’Brien L, Alto WA, Wong J. Does concurrent in utero exposure to buprenorphine and antidepressant medications influence the course of neonatal abstinence syndrome? J Matern Fetal Neonatal Med. 2015;8:1-3.
O’Connor AB, Collett A, Alto WA, O’Brien LM. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. J Midwifery Womens Health. 2013;58(4):383-8.
O’Connor AB, O’Brien L, Alto WA. Are there gender related differences in neonatal abstinence syndrome following exposure to buprenorphine during pregnancy? J Perinat Med. 2013;41(5):621-3.